Weight gain and insulin treatment

Diabetes and Metabolism

Volumn 31, Issue 4 II, 2005, Pages

  Larger, E ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Insulin detemir; Insulin treatment; Type 1 diabetes; Type 2 diabetes; Weight gain

Indexed keywords

GLIBENCLAMIDE; INSULIN DERIVATIVE; INSULIN DETEMIR; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

CARDIOVASCULAR RISK; DRUG EFFECT; FAMILY HISTORY; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LONG TERM CARE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 25444470287     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(05)88268-0     Document Type: Review

References (27)

1. Fritsche A, Häring H. At last, a weight neutral insulin? Int J Obes Relat Metab Disord 2004;28 (Suppl. 2):S41-S46.
2. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. [Insulin and weight gain: myth or reality?]. Diabetes Metab 2001;27:5S23-5S27.
3. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
4. The Diabetes Control and Complication Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complication Trial. Diabetes Care 1995;18: 1415-27.
5. Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994;43:313-7.
6. The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711-21.
7. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140-6.
8. Leiter L, Zinman B, Simkins S, Kenny D. Influence of intensive diabetes treatment on body weight and composition of adults in the diabetes control and complications trial (DCCT). Diabetes 1995;43 (Suppl.):29A [abstract].
9. Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003;52:2623-9.
10. The Diabetes Control and Complication Trial/Epidemiology of Diabetes Intervention and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-303.
11. Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care 1999;22 (Suppl 2):B35-B39.
12. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care 2001;24:1849-50.
13. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.
14. Lindström T, Eriksson P, Olsson AG, Arnqvist HJ. Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care 1994;17:719-21.
15. Gray A, Raikou M, McGuire A, et al., on behalf of the United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). Br Med J 2000;320:1373-8.
16. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998;97:996-1001.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
18. Chapman TM, Perry CM. Insulin Detemir. A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004;64:2577-95.
19. Kurtzhals P, Schäffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
20. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9.
21. Home P, Bartley P, Russell-Jones D, et al., on behalf of the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7.
22. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36.
23. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.
24. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-82.
25. Standl E, Lang H, Roberts A The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004;6:579-88.
26. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.
27. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.